TDACs appear to represent an important resource for biotherapy of patients with cancer.

Immune monitoring of biotherapy clinical trials has undergone a considerable change in recent years.

In conclusion, biotherapy remains an active treatment strategy for initial approach in patients with NETs.

After 6 courses of concomitant biochemotherapy, biotherapy was continued in patients who had a clinical benefit.

Activated lymphocytes derived from tumor biopsies are very important as a source of biotherapy for cancer.

It is important to construct an effective method to identify and isolate CSCs for biotherapy of cancer.

A sustained improvement in all evaluated immunologic parameters was observed in the 36 patients treated with maintenance biotherapy.

This study provides evidence for the practical usefulness of anti-CD3 antibody stimulation of lymphocytes used in the biotherapy of cancer.

Further investigation on patients' selection, molecular profiles, treatment sequence or combination and optimisation of current and novel biotherapy agents is required.

Virus-targeted therapy for tumors can effectively prolong the survival rate of patients and has become a new trend for cancer biotherapy.

In the present study, anti-CD3 antibody was used as a substitute for specific antigen in the generation of effector cells for biotherapy.

We concluded that the triple-regulated SG600-p53, as a more potent and safer antitumor therapeutic, could provide a new strategy for cancer biotherapy.

IRX-2 application to future cancer biotherapies could improve their effectiveness by bolstering T-cell resistance to tumor-induced immunosuppression.

New biotherapies are a major part of the evolving strategies to fight lung cancer and actually represent a true revolution for subsets of patients.

TDACs appear to represent an important resource for biotherapy of patients with cancer.

Immune monitoring of biotherapy clinical trials has undergone a considerable change in recent years.